Skip to main content

Gut OncoMicrobiome Signatures (GOMS) associated with cancer incidence, prognosis and prediction of treatment response.

Objective

Beyond the role the intestinal metagenome plays in regulating multiple physBeyond its role in regulating multiple physiological functions that impact health, the intestinal metagenome is implicated in cancer initiation, progression and responses to therapies, even for extraintestinal neoplasia. Hence, there is an urgent need to fully identify and functionally characterize minimalist commensal ecosystems relevant to cancer, with reliable and robust methods, to validate cancer-associated gut microbiome fingerprints of high clinical relevance, and to develop diagnosis tools that will become part of the oncological arsenal for the optimization and personalization of therapy. Based on retro-and pro-spective studies, with large discovery and validation cohorts enrolling >9,000 cancer patients across 10 countries, ancillary to ongoing innovative clinical trials or FDA/EMA approvals across 4 frequent cancer types, ONCOBIOME will pursue the following aims: 1/ identify and validate core or cancer-specific Gut OncoMicrobiome Signatures (GOMS) associated with cancer occurrence, prognosis, response to, or progression on, therapy (polychemotherapy, immune checkpoint inhibitors, dendritic cell vaccines) or adverse effects, 2/ decipher the functional relevance of these cancer-associated gut commensal ecosystems in the regulation of host metabolism, immunity and oncogenesis, 3/ integrate these GOMS with other oncology hallmarks (clinics, genomics, immunomics, metabolomics) 4/ design optimal companion tests, based on those integrated signatures to predict cancer occurrence and progression. With high carat interdisciplinary experts, ONCOBIOME expects to validate cancer or therapy-specific Gut OncoMicrobiome Signatures (GOMS) across breast, colorectal, melanoma and lung cancers adjusting for covariates, to unravel the mode of action of these GOMS in innovative platforms, thus lending support to the design of cancer preventive campaigns using well characterized pre-and pro-biotics.

Field of science

  • /medical and health sciences/clinical medicine/dermatology/melanoma
  • /natural sciences/biological sciences/ecology/ecosystems
  • /medical and health sciences/clinical medicine/oncology/cancer
  • /medical and health sciences/clinical medicine/oncology/cancer/breast cancer
  • /medical and health sciences/basic medicine/pharmacology and pharmacy/pharmaceutical drug/vaccines

Call for proposal

H2020-SC1-2018-Single-Stage-RTD
See other projects for this call

Funding Scheme

RIA - Research and Innovation action

Coordinator

INSTITUT GUSTAVE ROUSSY
Address
Rue Camille Desmoulins 39
94805 Villejuif
France
Activity type
Research Organisations
EU contribution
€ 2 299 375

Participants (17)

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France
EU contribution
€ 898 275
Address
Rue De Tolbiac 101
75654 Paris
Activity type
Research Organisations
UNIVERSITA DEGLI STUDI DI TRENTO
Italy
EU contribution
€ 1 545 868,75
Address
Via Calepina 14
38122 Trento
Activity type
Higher or Secondary Education Establishments
FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI
Italy
EU contribution
€ 223 750
Address
Via Venezian 1
20133 Milan
Activity type
Research Organisations
Masarykova univerzita
Czechia
EU contribution
€ 842 296,25
Address
Zerotinovo Namesti 9
60177 Brno Stred
Activity type
Higher or Secondary Education Establishments
UNIVERSITATSKLINIKUM ERLANGEN
Germany
EU contribution
€ 847 125
Address
Maximiliansplatz 2
91054 Erlangen
Activity type
Higher or Secondary Education Establishments
STICHTING KATHOLIEKE UNIVERSITEIT
Netherlands
EU contribution
€ 791 358,75
Address
Geert Grooteplein Noord 9
6525 EZ Nijmegen
Activity type
Higher or Secondary Education Establishments
IIGM FOUNDATION
Italy
EU contribution
€ 862 936,25
Address
Piazza Bernini 5
10138 Torino
Activity type
Research Organisations
THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE
United Kingdom
EU contribution
€ 666 498,75
Address
Trinity Lane The Old Schools
CB2 1TN Cambridge
Activity type
Higher or Secondary Education Establishments
KAROLINSKA INSTITUTET
Sweden
EU contribution
€ 2 801 953,75
Address
Nobels Vag 5
17177 Stockholm
Activity type
Higher or Secondary Education Establishments
CENTRE HOSPITALIER DE L'UNIVERSITEDE MONTREAL
Canada
EU contribution
€ 0
Address
850 Rue Saint-denis
H2XOA9 Montreal Quebec
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
UNICANCER
France
EU contribution
€ 431 978,75
Address
101 Rue De Tolbiac
75013 Paris
Activity type
Research Organisations
CHARITE - UNIVERSITAETSMEDIZIN BERLIN

Participation ended

Germany
EU contribution
€ 0
Address
Chariteplatz 1
10117 Berlin
Activity type
Higher or Secondary Education Establishments
GBG FORSCHUNGS GMBH
Germany
EU contribution
€ 619 312,50
Address
Martin Behaim Strasse 12
63263 Neu-isenburg
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
HALIODX
France
EU contribution
€ 521 322,50
Address
163 Avenue De Luminy Parc Scientifique De Luminy Luminy Biotec Entreprises
13288 Marseille
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EVERIMMUNE
France
EU contribution
€ 519 000
Address
39 Rue Camille Desmoulins
94800 Villejuif
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
ALGOE SA
France
EU contribution
€ 420 437,50
Address
9 Bis Route De Champagne
69130 Ecully Cedex
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
PHILIPPS UNIVERSITAET MARBURG
Germany
EU contribution
€ 703 062,50
Address
Biegenstrasse 10
35037 Marburg
Activity type
Higher or Secondary Education Establishments